Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer

Miruna Grecea,1 Olga Soritau,2 Daniel Dulf,1,2 Tudor Eliade Ciuleanu,1,2 Mihnea Zdrenghea2,3 1Iuliu Hatieganu University of Medicine and Pharmacy, Department of Oncology, Cluj-Napoca, Romania; 2Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	immune checkpoint blockade predictive biomarkers pd-l1 expression microbiome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c2900d088b2e4e429ffb9a4c5748f9b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2900d088b2e4e429ffb9a4c5748f9b3
record_format	dspace
spelling	oai:doaj.org-article:c2900d088b2e4e429ffb9a4c5748f9b32021-11-16T18:47:50ZPotential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer1178-6930https://doaj.org/article/c2900d088b2e4e429ffb9a4c5748f9b32021-11-01T00:00:00Zhttps://www.dovepress.com/potential-biomarkers-for-the-efficacy-of-pd-1-pd-l-blockade-in-cancer-peer-reviewed-fulltext-article-OTThttps://doaj.org/toc/1178-6930Miruna Grecea,1 Olga Soritau,2 Daniel Dulf,1,2 Tudor Eliade Ciuleanu,1,2 Mihnea Zdrenghea2,3 1Iuliu Hatieganu University of Medicine and Pharmacy, Department of Oncology, Cluj-Napoca, Romania; 2Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Cluj-Napoca, RomaniaCorrespondence: Mihnea ZdrengheaIuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Republicii 34-36, Cluj-Napoca, 400015, RomaniaTel +40741100480Fax +40264598606Email mzdrenghea@umfcluj.roAbstract: A decade ago, immune checkpoint blockade emerged as a major breakthrough in oncology, proposing a novel approach by which immune brakes could be released to enhance antitumor responses. Despite apparently modest improvement of the median duration of response, a spectacular doubling of long-term responses as compared to the available standard of care was seen, for instance, in metastatic melanoma. It soon became obvious that the percentage of patients responding to these novel approaches is relatively small, and the importance of an accurate prediction of responders became more and more clear. Strong predictive markers would allow for the administration of immune checkpoint blocker therapy to the patients most likely to benefit from it, and sparing the potential non-responders of a treatment which is far from innocuous, being associated with significant side-effects and, not least, an important price tag. A number of potential response predictors have already been investigated and partly validated, but they do not cover the major unmet need encountered in the current clinical setting. Here, we review biomarkers for immune checkpoint blockade efficacy, either clinically validated and currently in use, or which have been proposed as candidates and are currently under investigation.Keywords: immune checkpoint blockade, predictive biomarkers, PD-L1 expression, microbiomeGrecea MSoritau ODulf DCiuleanu TEZdrenghea MDove Medical Pressarticleimmune checkpoint blockadepredictive biomarkerspd-l1 expressionmicrobiomeNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoTargets and Therapy, Vol Volume 14, Pp 5275-5291 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint blockade predictive biomarkers pd-l1 expression microbiome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune checkpoint blockade predictive biomarkers pd-l1 expression microbiome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Grecea M Soritau O Dulf D Ciuleanu TE Zdrenghea M Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
description	Miruna Grecea,1 Olga Soritau,2 Daniel Dulf,1,2 Tudor Eliade Ciuleanu,1,2 Mihnea Zdrenghea2,3 1Iuliu Hatieganu University of Medicine and Pharmacy, Department of Oncology, Cluj-Napoca, Romania; 2Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Cluj-Napoca, RomaniaCorrespondence: Mihnea ZdrengheaIuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Republicii 34-36, Cluj-Napoca, 400015, RomaniaTel +40741100480Fax +40264598606Email mzdrenghea@umfcluj.roAbstract: A decade ago, immune checkpoint blockade emerged as a major breakthrough in oncology, proposing a novel approach by which immune brakes could be released to enhance antitumor responses. Despite apparently modest improvement of the median duration of response, a spectacular doubling of long-term responses as compared to the available standard of care was seen, for instance, in metastatic melanoma. It soon became obvious that the percentage of patients responding to these novel approaches is relatively small, and the importance of an accurate prediction of responders became more and more clear. Strong predictive markers would allow for the administration of immune checkpoint blocker therapy to the patients most likely to benefit from it, and sparing the potential non-responders of a treatment which is far from innocuous, being associated with significant side-effects and, not least, an important price tag. A number of potential response predictors have already been investigated and partly validated, but they do not cover the major unmet need encountered in the current clinical setting. Here, we review biomarkers for immune checkpoint blockade efficacy, either clinically validated and currently in use, or which have been proposed as candidates and are currently under investigation.Keywords: immune checkpoint blockade, predictive biomarkers, PD-L1 expression, microbiome
format	article
author	Grecea M Soritau O Dulf D Ciuleanu TE Zdrenghea M
author_facet	Grecea M Soritau O Dulf D Ciuleanu TE Zdrenghea M
author_sort	Grecea M
title	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
title_short	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
title_full	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
title_fullStr	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
title_full_unstemmed	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
title_sort	potential biomarkers for the efficacy of pd-1-pd-l blockade in cancer
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c2900d088b2e4e429ffb9a4c5748f9b3
work_keys_str_mv	AT greceam potentialbiomarkersfortheefficacyofpd1pdlblockadeincancer AT soritauo potentialbiomarkersfortheefficacyofpd1pdlblockadeincancer AT dulfd potentialbiomarkersfortheefficacyofpd1pdlblockadeincancer AT ciuleanute potentialbiomarkersfortheefficacyofpd1pdlblockadeincancer AT zdrengheam potentialbiomarkersfortheefficacyofpd1pdlblockadeincancer
_version_	1718426264453251072

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer

Ejemplares similares